(Q42873293)

9 November 2017

title

Assessment of activity levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 genes by population pharmacokinetics of dextromethorphan (English)

1 reference

9 November 2017

1 reference

K Abduljalil

1

1 reference

9 November 2017

D Frank

2

1 reference

9 November 2017

A Gaedigk

3

1 reference

9 November 2017

T Klaassen

4

1 reference

9 November 2017

D Tomalik-Scharte

5

1 reference

9 November 2017

A Jetter

6

1 reference

9 November 2017

U Jaehde

7

1 reference

9 November 2017

J Kirchheiner

8

1 reference

9 November 2017

U Fuhr

9

1 reference

9 November 2017

language of work or name

English

0 references

publication date

29 September 2010

1 reference

Clinical Pharmacology & Therapeutics

9 November 2017

published in

1 reference

9 November 2017

volume

88

1 reference

9 November 2017

issue

5

1 reference

9 November 2017

page(s)

643-651

1 reference

Physiologically based modelling of inhibition of metabolism and assessment of the relative potency of drug and metabolite: dextromethorphan vs. dextrorphan using quinidine inhibition

9 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.137

7 January 2021

The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.137

7 January 2021

Dextromethorphan to dextrorphan urinary metabolic ratio does not reflect dextromethorphan oral clearance

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.137

7 January 2021

CYP2D6- and CYP3A-dependent metabolism of dextromethorphan in humans

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.137

7 January 2021

The urinary excretion of dextromethorphan and three metabolites in dogs and humans

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.137

7 January 2021

In-vivo indices of CYP2D6 activity: comparison of dextromethorphan metabolic ratios in 4-h urine and 3-h plasma

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.137

7 January 2021

Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.137

7 January 2021

The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.137

7 January 2021

Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.137

7 January 2021

Intermediate metabolizer: increased side effects in psychoactive drug therapy. The key to cost-effectiveness of pretreatment CYP2D6 screening?

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.137

7 January 2021

Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.137

7 January 2021

Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.137

7 January 2021

Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.137

7 January 2021

CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.137

7 January 2021

Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.137

7 January 2021

The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.137

7 January 2021

Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.137

7 January 2021

A model with separate hepato-portal compartment ("first-pass" model): fitting to plasma concentration-time profiles in humans

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.137

7 January 2021

Population pharmacokinetics of nicotine and its metabolites I. Model development

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.137

7 January 2021

AmineDB: large scale docking of amines with CYP2D6 and scoring for druglike properties--towards defining the scope of the chemical defense against foreign amines in humans.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.137

7 January 2021

Expression, purification, biochemical characterization, and comparative function of human cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 allelic isoforms

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.137

7 January 2021

Pinoline may be used as a probe for CYP2D6 activity

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.137

7 January 2021

Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.137

7 January 2021

The molecular and enzyme kinetic basis for the diminished activity of the cytochrome P450 2D6.17 (CYP2D6.17) variant. Potential implications for CYP2D6 phenotyping studies and the clinical use of CYP2D6 substrate drugs in some African populations

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.137

7 January 2021

Characterization of cytochrome P450 2D6.1 (CYP2D6.1), CYP2D6.2, and CYP2D6.17 activities toward model CYP2D6 substrates dextromethorphan, bufuralol, and debrisoquine

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.137

7 January 2021

Methodological uncertainty in quantitative prediction of human hepatic clearance from in vitro experimental systems.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.137

7 January 2021

CYP2D6 polymorphism in a Gabonese population: contribution of the CYP2D6*2 and CYP2D6*17 alleles to the high prevalence of the intermediate metabolic phenotype

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.137

7 January 2021

Impaired expression of CYP2D6 in intermediate metabolizers carrying the *41 allele caused by the intronic SNP 2988G>A: evidence for modulation of splicing events.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.137

7 January 2021

A novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.137

7 January 2021

Prediction of the effects of genetic polymorphism on the pharmacokinetics of CYP2C9 substrates from in vitro data

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.137

7 January 2021

Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.137

7 January 2021

Intravenous dextromethorphan to human volunteers: relationship between pharmacokinetics and anti-hyperalgesic effect

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.137

7 January 2021

Safety, tolerability, and pharmacokinetics of the N-methyl-D-aspartate antagonist dextrorphan in patients with acute stroke. Dextrorphan Study Group

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.137

7 January 2021

Bioavailability of dextromethorphan (as dextrorphan) from sustained release formulations in the presence of guaifenesin in human volunteers

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.137

7 January 2021

Effect of gender, sex hormones, time variables and physiological urinary pH on apparent CYP2D6 activity as assessed by metabolic ratios of marker substrates

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.137

7 January 2021

Pharmacogenetic-based clinical scores: a useful, simple tool to predict tamoxifen-based CYP2D6 phenotype?

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.137

7 January 2021

Assessment of urinary mephenytoin metrics to phenotype for CYP2C19 and CYP2B6 activity

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.137

7 January 2021

Plasma 4beta-hydroxycholesterol: an endogenous CYP3A metric?

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.137

7 January 2021

Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.137

7 January 2021

Cytochrome P4502D6 (CYP2D6) gene locus heterogeneity: characterization of gene duplication events.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.137

7 January 2021

Identifiers

DOI

10.1038/CLPT.2010.137

1 reference

9 November 2017

1 reference